Sino Biopharmaceutical Limited

SEHK:1177 Stock Report

Market Cap: HK$58.4b

Sino Biopharmaceutical Management

Management criteria checks 1/4

Sino Biopharmaceutical's CEO is Eric S. Y. Tse, appointed in Jul 2022, has a tenure of 2.42 years. total yearly compensation is CN¥49.69M, comprised of 45.4% salary and 54.6% bonuses, including company stock and options. directly owns 22.27% of the company’s shares, worth HK$13.02B. The average tenure of the management team and the board of directors is 1.9 years and 9.6 years respectively.

Key information

Eric S. Y. Tse

Chief executive officer

CN¥49.7m

Total compensation

CEO salary percentage45.4%
CEO tenure2.4yrs
CEO ownership22.3%
Management average tenure1.9yrs
Board average tenure9.6yrs

Recent management updates

Recent updates

Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?

Dec 08
Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Oct 02
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sep 02
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Jul 12
Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

May 21
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Apr 21
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Apr 03
What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20
Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

CEO Compensation Analysis

How has Eric S. Y. Tse's remuneration changed compared to Sino Biopharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥2b

Dec 31 2023CN¥50mCN¥23m

CN¥2b

Jun 30 2023n/an/a

CN¥1b

Mar 31 2023n/an/a

CN¥2b

Dec 31 2022n/an/a

CN¥2b

Sep 30 2022n/an/a

CN¥5b

Jun 30 2022n/an/a

CN¥8b

Mar 31 2022n/an/a

CN¥14b

Dec 31 2021CN¥23mCN¥6m

CN¥15b

Sep 30 2021n/an/a

CN¥12b

Jun 30 2021n/an/a

CN¥10b

Mar 31 2021n/an/a

CN¥4b

Dec 31 2020CN¥25mCN¥7m

CN¥3b

Sep 30 2020n/an/a

CN¥2b

Jun 30 2020n/an/a

CN¥3b

Mar 31 2020n/an/a

CN¥3b

Dec 31 2019CN¥6mCN¥870k

CN¥3b

Compensation vs Market: Eric S. Y.'s total compensation ($USD6.81M) is above average for companies of similar size in the Hong Kong market ($USD848.16K).

Compensation vs Earnings: Eric S. Y.'s compensation has increased by more than 20% in the past year.

CEO

Eric S. Y. Tse (28 yo)

2.4yrs

Tenure

CN¥49,691,000

Compensation

Mr. Eric S. Y. Tse serves as an Executive Director at Sino Biopharmaceutical Limited since October 23, 2019 and serves as its Chief Executive Officer since July 28, 2022. Mr. Tse joined Sino Biopharmaceuti...

Leadership Team

NamePositionTenureCompensationOwnership
Y. Y. Tse
Executive Chairwoman of the Board9.5yrsCN¥49.69m0.033%
HK$ 19.3m
Eric S. Y. Tse
CEO & Executive Director2.4yrsCN¥49.69m22.27%
HK$ 13.0b
Ping Tse
Founder & Senior Executive Vice Chairman4.3yrsCN¥49.53m9.11%
HK$ 5.3b
Cheung Ling Cheng
Executive Vice Chairwoman of the Board7.7yrsCN¥43.13m16.31%
HK$ 9.5b
Zhoushan Tian
Executive Directorno dataCN¥1.91mno data
Hsin Tse
Senior VP & Executive Directorno dataCN¥6.41m1.96%
HK$ 1.1b
Chun Ling Li
Chief Financial Officer1.9yrsno datano data
Song Jin
Vice President of Public Affairsno datano datano data
Sean Chen
Chief Strategy Officer1.9yrsno datano data
Chau Ling Yu
Assistant VP & Financial Controllerno datano datano data
Oi Nin Chan
Company Secretary9.3yrsno datano data
Toogood Ben
CEO of invoX & Head of Globalization1.9yrsno datano data

1.9yrs

Average Tenure

53yo

Average Age

Experienced Management: 1177's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Y. Y. Tse
Executive Chairwoman of the Board9.5yrsCN¥49.69m0.033%
HK$ 19.3m
Eric S. Y. Tse
CEO & Executive Director5.2yrsCN¥49.69m22.27%
HK$ 13.0b
Ping Tse
Founder & Senior Executive Vice Chairman4.3yrsCN¥49.53m9.11%
HK$ 5.3b
Cheung Ling Cheng
Executive Vice Chairwoman of the Board7.7yrsCN¥43.13m16.31%
HK$ 9.5b
Zhoushan Tian
Executive Director9.7yrsCN¥1.91mno data
Hsin Tse
Senior VP & Executive Directorno dataCN¥6.41m1.96%
HK$ 1.1b
Zhengfei Lu
Independent Non-Executive Director19.1yrsCN¥376.00kno data
Dakui Li
Independent Non-Executive Director20.3yrsCN¥376.00kno data
Lu Fu Zhang
Independent Non-Executive Director9.7yrsCN¥376.00kno data
Hong Lu
Independent Non-Executive Director9.7yrsCN¥342.00kno data
Kwok Tung Li
Independent Non-Executive Director4yrsCN¥376.00k0.00039%
HK$ 227.9k

9.6yrs

Average Tenure

60yo

Average Age

Experienced Board: 1177's board of directors are considered experienced (9.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 23:52
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sino Biopharmaceutical Limited is covered by 51 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin LiuBNP Paribas Securities (Asia)
Ling ZhangBNP Paribas Securities (Asia)
Wai Chak YuenBOCI Research Ltd.